![]() |
|
|
Vol. 283, Issue 3, 1520-1528, 1997
School of Dietetics and Human Nutrition and Center for Indigenous Peoples' Nutrition and Environment, Macdonald Campus of McGill University, Quebec, Canada
| |
Abstract |
|---|
|
|
|---|
The treatment of breast cancer by retinoic acid (RA) may be mediated by lipid peroxidation. Expression of metallothionein (MT) in cancer cells, however, can protect against lipid peroxidation by scavenging hydroxyl radicals. In this study, a two-by-six factorial design was used to investigate the interactive effects of all-trans-RA and zinc (Zn)-induced MT on the growth of two human breast cancer cell lines differing in basal expression of MT and estrogen receptors; MCF7 cells express estrogen receptor, BT-20 cells do not. Cells were treated with Zn to induce MT and then treated with six RA concentrations. Cell proliferation, lipid peroxidation, MT protein, MT mRNA and glutathione concentrations were measured. BT-20 cells expressed higher constitutive MT concentrations than MCF7 cells. MT was significantly increased by Zn treatment in BT-20 cells but not in MCF7 cells. Low RA concentrations stimulated growth proliferation but higher concentrations inhibited cell proliferation. Elevated RA concentrations increased lipid peroxidation as measured by thiobarbituric acid reactive substances. There was a significant negative correlation between lipid peroxidation and cell proliferation. Growth inhibition and lipid peroxidation were reduced by Zn pretreatment in BT-20 cells but not in MCF7 cells. RA increased MT levels in both cell lines, which suggests that RA may generate free radicals which will induce MT mRNA expression. Glutathione did not appear to be a significant factor. Therefore, induction of MT by Zn may modulate the growth inhibitory effects of RA in human breast cancer cells. One mechanism of growth inhibition may be through increased lipid peroxidation. Induction of MT by RA may be one explanation for acquired RA resistance in cancer.
| |
Introduction |
|---|
|
|
|---|
Suggested
mechanisms of inhibition of cancer cell proliferation by RA include
induction of differentiation or induction of apoptosis (Smith et
al., 1992
), modulation of gene expression though nuclear receptor
binding, modulation of oncogene expression (Doyle et al.,
1989
; Hino et al., 1989
; Scheibe et al., 1991
) or
modification of cell membrane glycoproteins (Chan and Wolf, 1987
) and
glycolipids (Chen et al., 1989
), which could alter
cell-to-cell communication, cell adhesion and shape. However, none of
these mechanisms fully explain how cancer cell growth may be resistant to or stimulated by RA treatment as observed previously (Lotan, 1979
).
RA at low concentrations may reduce cellular oxidative stress by
scavenging lipid peroxyl radicals (Samokyszyn and Marnet, 1990
) and
decreasing levels of superoxide (Witz et al., 1980
). Moreover, 13-cis-RA was shown to directly increase levels of
superoxide anion, hydrogen peroxide and hydroxyl anions in isolated
chick neural crest cells (Davis et al., 1990
). RA can also
stimulate the activity of
-6-desaturase which could increase levels
of PUFA in the membrane (Alam et al., 1984
). An increase of
either oxygen free radicals or PUFA could lead to increased levels of lipid peroxidation.
One feature of rapidly proliferating cells is low levels of lipid
peroxidation (Rice-Evans and Burdon, 1993
) which may be caused by lower
PUFA membrane content. Decreased PUFA content in cancer cells is
associated with malignant transformation, tumorigenicity and metastasis
(Friedberg et al., 1986
). Alterations in membrane fatty acid
composition may be caused by the loss or decrease of the
-6-desaturase activity observed in malignant tumors (Morton et
al., 1979
). Increasing PUFA content of cells increases sensitivity to oxygen radical toxicity (Spitz et al., 1992
), inhibits
cell proliferation (Perkins and Duncan, 1991
) and increases lipid
peroxidation (Zhang and Sevanian, 1991
). Therefore, modulation of
cancer cell growth may be possible through manipulation of cellular
membrane PUFA to increase the degree of lipid peroxidation.
One possible determinant of oxidative stress in breast cancer cells is
MT. MT is a low molecular weight protein high in cysteine content that
is involved in Zn homeostasis, heavy metal protection and free radical
scavenging. Expression of MT can be induced by Zn and other metals,
glucocorticoids, interferon, cAMP and interleukin-1, physical stresses
including food restriction and extreme cold, numerous drugs,
herbicides, solvents, alkylating compounds and ionizing irradiation
(Dunn et al., 1987
). In breast cancer, tumor overexpression
of MT is associated with decreased patient survival (Fresno et
al., 1993
) and shorter disease-free intervals (Morales et
al., 1994
; Goulding et al., 1995
). An inverse
correlation between the expression of ER and MT has been identified
(Fresno et al., 1993
; Oyama et al., 1996
)
although not in all studies (Reid et al., 1992
; Goulding
et al., 1995
). MT has conferred resistance to the
antineoplastic drugs, cis-diamminedichloroplatinum,
chlorambucil and melphalan (Kelley et al., 1988
).
Possible resistance to the effects of RA by MT has not been
investigated.
The roles of lipid peroxidation in determining the efficacy of RA treatment in breast cancer cells have not been elucidated. It is also not known if MT can modulate the antiproliferative effects of RA. This study was designed to investigate the effects of RA on breast cancer cell proliferation in conjunction with levels of lipid peroxidation as a possible mechanism. We also examine the modulation of RA effects by different concentrations of MT present in the cells. We hypothesize that increased MT will decrease lipid peroxidation caused by RA, which will alleviate RA antiproliferative effects.
| |
Materials and Methods |
|---|
|
|
|---|
Cell culture. Human breast cancer cell lines, MCF7 (ER positive) and BT-20 (ER negative), were purchased from American Type Culture Collection (Rockville, MD). Cells were routinely propagated in Dulbecco's Modified Essential Medium and supplemented with 10% non-heat-inactivated fetal bovine serum in humidified 5% CO2/95% air at 37°C. Zn concentration of the media was 3.3 ± 1 nM. Experiments were conducted with use of cells cultured in T75 tissue flask or 96-well plates.
Metallothionein induction with Zn.
Expression of MT in both
cell lines was studied after treatment with 50, 100 or 200 µM
ZnCl2 for 48 h. MT was measured by a
competitive ELISA (Chan et al., 1992
). Total protein was
measured with the Bradford assay (Bradford, 1976
), so MT was
standardized to nanograms per milligram of protein.
Interaction between Zn and RA.
A two-by-six factorial
experiment was conducted. Cells grown in both 96-well plates or T75
tissue flask were pretreated with 200 µM Zn (14 days) and then
treated with RA (1 × 10
10 to 5 × 10
5 M for 7 days). RA solutions were prepared
fresh in 95% ethanol. All manipulations were performed under yellow
light. Total ethanol used as a vehicle for RA amounted to <0.1% (a
concentration that has been shown not to affect cellular
proliferation). Medium was changed once on day 4. On day 8, cell
proliferation was measured. Cells were harvested with 0.29% trypsin/1
mM ethylenediaminetetraacetic acid. Aliquots of cells were used for
lipid peroxidation measurement, MT measurement or glutathione
measurement or treated with Trizol for RNA isolation.
Cell proliferation.
The experiment was conducted with cells
plated to 96-well plates. Cell proliferation was measured by the
Promega CellTiter 96 Aqueous Non-Radioactive Cell Proliferation Assay
(Cory et al., 1991
). A tetrazolium salt (MTS) was bioreduced
by cells to a media-soluble formazan, which was measured
spectrophotometrically at A490 with a
Vmax microplate reader (Molecular Devices
Corporation, Menlo Park, CA). The formation of formazan from MTS was
directly proportional to the number of cells present. All values were
represented as percent of controls.
Lipid peroxidation.
Harvested cells were lysed in 1.25 ml
cold 154 mM potassium chloride and 5 µM butylated hydroxytoluene with
a sonicator. The lysed cell suspension (0.5 ml) was added to 3 ml cold
1% (w/v) phosphoric acid. As an indication of the degree of lipid
peroxidation, a TBARS assay was performed (Sunderman et al.,
1985
). Protein concentrations were measured by the Bradford assay
(Bradford, 1976
) to standardize between samples.
MT measurement.
MT in the harvested cells were measured on
both the protein and mRNA level. MT protein level was measured by ELISA
as described by Chan et al. (1992)
. Total RNA was isolated
with Trizol reagent (Gibco BRL, Grand Island, NY). RNA (10 µg) was
denatured and subjected to electrophoresis through a 1% agarose gel
followed by transfer to Hybond nylon membrane (Amersham, Arlington
Heights, IL). Northern blots were hybridized to
32P-labeled human hMT-IIA genomic probe
(Koropatnick et al., 1989
). Autoradiography was done with
X-OMAT AR Scientific Imaging Film (Kodak, Rochester, NY) followed by
densitometry. Rehybridization of the same nylon membranes to an
18S-labeled probe allowed for standardized qualitative comparison
between samples.
Glutathione measurement.
Harvested cells were immediately
resuspended in 2.5% perchloric acid and stored at
80°C until
analysis. Total reduced and oxidized GSH was measured as described by
Anderson (1985)
. Total protein was measured so all values were
standardized to nanomoles GSH per milligram protein.
Statistical methods. All statistics were performed with Systat for Windows Version 5.02 (Systat Inc., Evanstown, IL). A two-way ANOVA was used for each cell line to examine the effects of Zn and RA treatments on lipid peroxidation, MT concentrations and GSH concentrations. The differences between treatment groups were determined by Tukey's HSD Multiple Comparison Test. The Pearson product moment correlation coefficient of cell proliferation and lipid peroxidation was calculated. A significance level of P < .05 was used for all tests.
| |
Results |
|---|
|
|
|---|
Basal MT concentrations were significantly higher in BT-20 cells at 30 ± 3 ng/mg protein (n = 3) than in MCF7 cells with MT concentrations of 5 ± 2 ng/mg protein (n = 3). With 48-h treatments with 50, 100 and 200 µM Zn, there was a dose-dependent increase of MT in the BT-20 cells (ANOVA, P < .05) (fig. 1). The a posteriori test results show that BT-20 cells treated with 200 µM Zn had significantly higher MT than the other groups. The concentration of MT increased 10-fold to 300 ± 77 ng/mg protein. There was, however, no significant induction of MT in MCF7 cells.
|
With RA treatments there was a consistent dose-dependent growth pattern
observed in both the control and Zn-treated groups for both cell lines
(fig. 2, A and B). There was an initial
increase of cell proliferation with lower concentrations of RA. At
higher concentrations of RA there was a dose-dependent decrease of cell proliferation. Two-way ANOVA results showed significant effects for
both Zn and RA treatments on cell growth in BT-20 cells. For the
control cells there was a slight stimulation of cell proliferation at
10
10 M RA. At 10
5 M and
5 × 10
5 M RA, cell proliferation was
inhibited to 89% and 83% of the control, respectively. Zn treatment
of BT-20 cells resulted in statistically significant higher cell
proliferation than the control cells (significant at RA treatments of
10
8 M, 10
6 M,
10
5 M and 5 × 10
5
M). Cell proliferation was stimulated in Zn-treated cells with 10
8 M and 10
6 M RA to
112% and 108% of control, respectively. On the other hand, a
significant growth inhibition occurred from treatment with 5 × 10
5 M RA, which was 91% of control.
|
In MCF7 cells, two-way ANOVA results showed no significant differences
in cell proliferation between the control and Zn-treated cells, and no
interaction between Zn and RA treatments. However, there were
significant differences in cell proliferation between levels of RA
treatment in MCF7 cells. Treatment with 10
10 M
RA increased cell proliferation 10% in control and in Zn-treated cells, but the effect was only statistically significant in Zn-treated cells (n = 96). There was no effect at
10
8 M RA. At 10
6 M,
10
5 M and 5 × 10
5
M RA, there was a significant dose-dependent inhibition of cell proliferation in both the control and Zn-treated cells.
Results from the TBARS assay showed a significant effect of RA and of
Zn on lipid peroxidation in BT-20 cells (fig.
3A). There was also a significant effect
of RA in MCF7 cells but, in contrast to BT-20 cells, there was no
significant effect of Zn (fig. 3B). Basal levels of lipid peroxidation
were 0.059 ± 0.009 mmol MDA chromogens per gram protein in BT-20
cells (n = 3) and 0.025 ± 0.001 mmol MDA
chromogens per gram protein in MCF7 cells (n = 3).
Significant increases of lipid peroxidation in BT-20 cells was observed
with 5 × 10
5 M RA. There were significant
increases in lipid peroxidation with 10
5 M and
5 × 10
5 M RA up to three times the basal
levels in MCF7 cells.
|
There was a statistically significant negative correlation between cell proliferation and lipid peroxidation in both cell lines (fig. 4, A and B). The Pearson product moment correlation coefficient calculated for these measures was R2 = 0.765 for BT-20 cells and R2 = 0.676 for MCF7 cells.
|
The 14-day, 200 µM Zn treatment increased MT levels in BT-20 cells
40-fold to 1200 ± 300 ng/mg protein (n = 3) (fig.
5, A and B). MT was also induced in both
cell lines after RA treatment (fig. 5, A-D). There was a significant
MT increase in Zn-treated BT-20 cells with 10
6
and 10
5 M RA treatments. The highest
concentration of MT was measured at 8000 ± 2000 ng/mg protein in
cells treated with Zn and 10
5 M RA. In MCF7
cells, MT levels were significantly higher in cells treated with 5 × 10
5 M RA (n = 3).
|
Qualitative investigation of the MT-2 mRNA levels supports MT protein
measurement. Measurement of MT-2 mRNA was detectable in both control
and Zn-treated BT-20 cells (fig. 6A).
Levels of MT-2 mRNA were 600% to 800% higher than controls in
Zn-treated BT-20 cells that also were treated with RA. In BT-20 cells
not treated with Zn, a dose-dependent effect of RA was also observed. With 5 × 10
5 M RA treatment, MT-2 mRNA
was increased to 200% of control. In MCF-7 cells, MT-2 mRNA was
detected in Zn-treated cells but not in control cells (fig. 6B). MT-2
mRNA increased dose-dependently with RA treatment in Zn-treated MCF7
cells. There was a 2.5- and 3-fold increase in Zn-treated MCF7 cells
with treatments of 10
5 and 5 × 10
5 M RA, respectively.
|
GSH measurement showed a significant effect of RA treatment but not of
Zn treatment on GSH concentrations in BT-20 cells (fig. 7A). There were significantly lower GSH
concentrations in BT-20 cells treated with 5 × 10
5 M RA. In Zn-treated BT-20 cells, GSH was
significantly decreased with the 5 × 10
5
M RA treatment compared with 10
10 M RA-treated
cells. In MCF7 cells, there was a significant effect of Zn treatment
but not RA treatment on GSH concentrations (fig. 7B). Basal GSH
concentrations measured in BT-20 cells were 70 ± 6 nmol/mg
protein (n = 3) and in MCF7 cells they were 32 ± 7 nmol/mg protein (n = 3).
|
| |
Discussion |
|---|
|
|
|---|
The expression of MT in breast cancer has significant health
implications. Increased expression of MT is associated with decreased patient survival and disease-free survival (Reid et al.,
1992
; Fresno et al., 1993
; Morales et al., 1994
;
Goulding et al., 1995
). Two human breast cancer cell lines
that differed in their ER expression were selected for this study with
the hypothesis that they would differ in their expression of MT.
Measurement of basal MT concentrations in the cell lines indicated
ER-negative BT-20 cells had 3-fold higher expression of MT (30 ng/mg
protein) than ER-positive MCF7 cells (10 ng/mg protein). In the BT-20
cell line, there was a significant increase of MT to 300 ng/mg protein
with Zn treatment (200 µM for 48 h), and an increase of up to
1200 ng/mg protein after Zn treatment for 14 days (200 µM).
Conversely, MT was not increased in MCF7 cells with the 48-h Zn
treatment and only slightly increased after a 14-day Zn treatment. MT
mRNA measured by Northern blot analysis confirms the protein
measurement. Similar low induction of MT in MCF7 cells has been
measured (Kelley et al., 1988
). After treatment with
cis-diamminedichloroplatinum, the MT concentration was
measured at only 95 ± 11% of control. Therefore, because of their differences in basal MT and MT inducibility, these two cell lines
may be used to investigate the possible role of MT in cancer cell
proliferation.
With this two-cell line model, we demonstrated that Zn-induced MT can
protect against cell growth inhibition caused by RA. Cell proliferation
in Zn-treated BT-20 cells was up to 15% higher than controls. However,
it has been argued that the protective effect may not caused solely by
MT, because Zn alone could be equally protective (Thomas et
al., 1986
). Because Zn is required for the function of many
enzymes involved with translation and transcription (Christianson,
1991
; Vallee, 1988
), Zn treatment may allow for increased activity and
increase the rate of cell proliferation. We have shown indirect
evidence demonstrating that MT expression may be a more critical
factor. After Zn treatment, MT concentrations in MCF7 cells (10 ng/mg
protein) were more than 100-fold lower than in BT-20 cells (1200 ng/mg
protein). Cell proliferation in Zn-treated MCF7 cells did not differ
from controls, whereas a clear protective effect was observed for the
same Zn treatment in BT-20 cells. These results indicate that it was
the increased levels of MT, and not Zn, that was responsible for the modulation RA inhibition of cell proliferation. Increased expression of
MT is one mechanism which has been implicated in acquired
antineoplastic drug resistance (Harris and Hochhauser, 1992
; Kelley
et al., 1988
; Lazo and Basu, 1991
). Resistance to
antineoplastic agents conferred by MT has also been demonstrated with
cis-diamminedichloroplatinum, chlorambucil and melphalan
(Kelley et al., 1988
).
In this study, RA was shown to stimulate and inhibit cell proliferation
in both cell lines depending on the treatment concentration. In BT-20
cells, cell proliferation was increased slightly with 10
10 M RA in both control and Zn-treated cells,
and significantly with 10
8 and
10
6 M RA in Zn-treated cells. Inhibition of
growth was observed with 10
5 and 5 × 10
5 M RA in control cells but only with 5 × 10
5 M RA in Zn-treated BT-20 cells. In both
control and Zn-treated MCF7 cells, cell proliferation was stimulated
with 10
10 M RA but inhibited with
10
6, 10
5 and 5 × 10
5 M RA. Antiproliferative effects of RA in
cancer have been reported previously, although the results obtained
have not been consistent in all cell types. RA used at the same
concentration was found to have variable effects on growth in different
cell lines (Lotan, 1979
). In another study, examining the effect of
atRA on the proliferation of 15 different cell lines, 9 cell lines were
RA sensitive and 6 were RA resistant (Takatsuka et
al., 1996
). The authors attributed the differences in RA
susceptibilities to the ability of the cells to metabolize RA. They
suggested that there was a metabolite of RA affecting the cell
proliferation although conditioned media from RA-metabolizing cells had
no effect on the resistant cells. Another study examining the
responsiveness of ovarian cancer cell lines suggested that the
effectiveness of RA was related to the level of differentiation of the
cell line (Caliaro et al., 1994
). They found that the most
undifferentiated metastatic cell line was resistant to RA. Because
increased MT has been associated with a decrease in differentiation and
the development of metastases (Oyama et al., 1996
; Schmid
et al., 1993
), the intrinsic level of MT or the inducibility
of MT expression may affect resistance to RA. Therefore, the variations
of RA dose used and the levels of MT may explain some the inconsistency
of the effect of RA observed previously.
Our results show that the different effects of RA on cell proliferation
may be explained by the modulation of cellular oxidative stress. At low
concentrations, RA could act as scavenger free radicals such as fatty
acid peroxyl radicals (Samokyszyn and Marnet, 1990
), lowering the
oxidative stress of the cell and allowing for increased proliferation.
In both MCF7 and BT-20 cells, there was a slight decrease of lipid
peroxidation with low doses of RA. This also corresponded with an
increase of cell proliferation. This inverse relationship between cell
proliferation and lipid peroxidation has been reported previously
(Rice-Evans and Burdon, 1993
). Conversely, increasing concentrations of
RA increased lipid peroxidation, which corresponded with decreased cell
proliferation. The mechanism of RA-mediated lipid peroxidation is not
fully known. However, there are two possible mechanisms. RA can
stimulate the activity of
-6-desaturase (Alam et al.,
1984
) resulting in an increase of polyunsaturated fatty acids, which
are oxidized most easily.
-6-Desaturase is the enzyme responsible
for inserting a double bond during PUFA synthesis. A loss or decreased
activity of this enzyme has been found in some malignant tumors. RA can also directly increase free radicals (Davis et al., 1990
),
which could result in increased lipid peroxidation.
The observed protective effect of MT further supports that the action
of RA is caused by increases of oxidative stress. MT can act as a free
radical scavenger (Thornalley and Vasak, 1985
) and protect against
lipid peroxidation (Naganuma et al., 1988
). In Zn-treated
BT-20 cells, there was a decrease in lipid peroxidation compared with
controls. Conversely, lipid peroxidation levels in MCF7 cells were not
affected by Zn treatment. This suggests that MT is acting to decrease
lipid peroxidation, which allows for increased cell proliferation. The
induction of MT by RA in breast cancer cells is a novel finding. This
could be one mechanism explaining the acquired resistance in
conventional RA treatments. RA is not commonly known as a MT inducer.
However, 13-cis-RA has been shown to induce hepatic MT in
mice and to produce a synergistic effect when combined with Zn (Cousins
and Swerdel, 1985
). On the other hand, elevated MT levels in mouse skin
tumors were not affected by RA (Hashiba et al., 1989
; Islam
and Toftgard, 1992
). The relationship between RA and MT induction
therefore requires further investigation.
GSH is another free radical scavenger implicated in antineoplastic drug
resistance (Chen et al., 1995
). In control and Zn-treated BT-20 cells, there was a RA dose-dependent decrease in GSH
concentrations. This decrease may be caused by GSH reacting with
increased free radicals or lipid peroxides. There was no difference in
GSH concentrations between zinc-treated and control BT-20 cells,
showing that there is little relationship between GSH and MT levels.
This suggests that GSH and MT may work through different pathways by
scavenging different free radicals. Because Zn treatment had an effect
on cell proliferation in BT-20 cells but GSH levels were unaffected by
zinc, it is unlikely that GSH is a critical molecule in protection against RA. RA has been shown to decrease GSH concentrations in cephalic chondrocytes, although RA had no effect on GSH concentrations in immature caudal chondrocytes (Teixeira et al., 1996
).
Therefore, the effect of RA may depend on the maturation and stage of
cell differentiation. In MCF7 cells, RA did not alter GSH, but Zn
treatment had an effect. This could result from the availability of
high levels of free Zn because there was no increase of MT with 200 µM Zn exposure. Zn has inhibited the activity of cytochrome c reductase (Kubow et al., 1984
) which could decrease the
formation of reactive species from RA. Free zinc could also displace
iron from lipid membranes which could reduce free radical formation from the Fenton reaction and subsequent lipid peroxidation (Girotti et al., 1985
). By reducing the formation of reactive species
or lipid peroxidation, degradation of GSH may have been protected indirectly by unbound Zn. However, because there was no significant decrease in lipid peroxidation or protective effect on cell
proliferation, it is unlikely that this sparing of GSH in MCF7 cells is
biologically important.
Results of our experiments show that both RA and Zn can affect the
growth of human breast cancer cells. Zn treatment induced MT in BT-20
cells and increased cell proliferation after RA treatment compared with
controls. Although Zn concentrations used in this experiment are higher
than physiological plasma concentrations (200 µM vs. 15 µM), it shows that MT can be induced in breast cancer cells. In
addition to Zn, MT can be induced by a variety of compounds and
situations such as glucocorticoids, interferon, interleukin-1, stress
and food restriction (Dunn et al., 1987
). Because these
compounds or situations may be present during cancer treatment, MT
could be induced in the tumor resulting in increased resistance to
treatment. Because MT does not provide protection against all cancer
therapies, more effective treatments may be selected once MT expression
of the cancer is determined.
Although the effects of RA on cancer are generally thought to result from interaction with nuclear receptors, our results suggest that modulation of lipid peroxidation may also be an important factor. Increasing RA increased lipid peroxidation and this was correlated with inhibition of cell proliferation. By increasing or decreasing the levels of lipid peroxidation, RA could regulate cell growth. The ability of the cell to protect itself from the increased lipid peroxidation could be an indicator for the efficacy of RA. Cells that express high levels of MT may be more resistant to its antiproliferative effects. Additionally, other oxygen free radical scavengers, such as catalase, superoxide dismutase or GSH, may affect the efficacy of RA, although GSH seemed to have little effect in this system. Levels of these scavengers may help explain how RA mediates growth in various cell lines.
The concentrations of RA used in this study range from physiological
plasma concentrations to pharmacological concentrations. The results
show the importance of RA concentrations for the stimulation or
inhibition of cell growth. In previous experiments, 1 × 10
6 M RA was the concentration used when cell
proliferation of mammary and epithelial cell lines was either
inhibited, stimulated or resistant (Lotan, 1979
). Pharmacological RA
doses result in transient plasma concentrations of 3 × 10
6 M, the range at which cell growth was
inhibited in MCF7 cells but not BT-20 cells, and stimulated in BT-20
cells with high MT. This study may also assist in explaining the
results of the ATBC (Rautalahti et al., 1995
) and CARET
(Omenn et al., 1994
) studies.
-Carotene can be converted
directly to RA so the
-carotene supplements could have resulted in
the growth stimulation of premalignant lung cancers.
In summary, we have shown that RA has antiproliferative effects on
breast cancer cells at concentrations exceeding
10
6 M. At lower concentrations, there is either
no effect or cell proliferation is stimulated. The effects of RA may at
least in part be caused by the modulation of lipid peroxidation levels. Furthermore, induction of MT by Zn can decrease levels of lipid peroxidation and modulate the growth inhibitory effects of retinoic acid in human breast cancer cells. Further studies may therefore examine methods to decrease MT in breast cancer cells to increase the
efficacy of treatment.
| |
Acknowledgments |
|---|
We thank Dr. X. Zhao for useful suggestions throughout the project, Dr. J. Koropatnick for the DNA probes for MT, Dr. U. Kuhnlein for the use of his laboratory facilities and E. del Heuval and S. Smith for their technical support.
| |
Footnotes |
|---|
Accepted for publication August 11, 1997.
Received for publication January 7, 1997.
1 Research funded by National Science and Engineering Research Council of Canada.
Send reprint requests to: Hing Man Chan, Centre for Indigenous Peoples' Nutrition and Environment, Department of Dietetics and Human Nutrition, McGill University, 21,111 Lakeshore Road, Ste. Anne de Bellevue, Quebec, Canada H9X 3V9.
| |
Abbreviations |
|---|
atRA, all-trans retinoic acid; ER, estrogen receptor; GSH, glutathione; MT, metallothionein; PUFA, polyunsaturated fatty acid; RA, retinoic acid; TBARS, thiobarbituric acid reactive substances; Zn, zinc; ELISA, enzyme-linked immunosorbent assay; ANOVA, analysis of variance.
| |
References |
|---|
|
|
|---|
-carotene and 13-cis retinoic acid.
Biochim. Biophys. Acta
792: 110-117, 1984[Medline].This article has been cited by other articles:
![]() |
F. Demichelis, H. Greulich, J. A. Macoska, R. Beroukhim, W. R. Sellers, L. Garraway, and M. A. Rubin SNP panel identification assay (SPIA): a genetic-based assay for the identification of cell lines Nucleic Acids Res., April 1, 2008; 36(7): 2446 - 2456. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||